{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:39:30Z","timestamp":1786718370592,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Saudi J Gastroenterol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/sjg.sjg_49_18","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T02:53:17Z","timestamp":1530845597000},"page":"326","source":"Crossref","is-referenced-by-count":21,"title":["Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-na\u00efve and experienced patients with chronic hepatitis B"],"prefix":"10.4103","volume":"24","author":[{"given":"HyunPhil","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YoungMin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoungIl","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KwangRo","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JaeMyung","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JungWon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinYoung","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MinSeob","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1319-3767.236136-1","first-page":"2212","volume-title":"Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"key-10.4103\/1319-3767.236136-2","first-page":"19","volume-title":"Seroepidemiology of type A and type B hepatitis in Seoul area","author":"Hong","year":"1982","journal-title":"Korean J Intern Med"},{"key":"key-10.4103\/1319-3767.236136-3","first-page":"1331","volume-title":"Seroepidemiologic survey on type B viral hepatitis in Inchon area","author":"Jang","year":"1983","journal-title":"Korean J Intern Med"},{"key":"key-10.4103\/1319-3767.236136-4","first-page":"153","volume-title":"Seroepidemiology of HBV infection in South Korea, 1995 through 1999","author":"Jang","year":"2001","journal-title":"Korean J Intern Med"},{"key":"key-10.4103\/1319-3767.236136-5","first-page":"642","volume-title":"Hepatitis B viral markers of Korean adults in the late 1990s: Survey data of 70,347 health screenees","author":"Joo","year":"1999","journal-title":"Korean J Gastroenterol"},{"key":"key-10.4103\/1319-3767.236136-6","unstructured":"Ministry of Health and Welfare, Korea Center for Disease Control and Prevention. Korea Health Statistics 2010: Korea National Health and Nutrition Examination Survey (KNHANES V-1). City; Korea Center for Disease Control and Prevention; 2011. p. 731."},{"key":"key-10.4103\/1319-3767.236136-7","first-page":"288","volume-title":"The clinical report of 1,078 cases of hepatocellular carcinomas: National Cancer Center experience","author":"Cheon","year":"2004","journal-title":"Korean J Hepatol"},{"key":"key-10.4103\/1319-3767.236136-8","first-page":"168","volume-title":"Natural history and survival rate of chronic liver diseases in Korea: 20 years prospective analysis","author":"Kim","year":"1994","journal-title":"Korean J Med"},{"key":"key-10.4103\/1319-3767.236136-9","first-page":"261","volume-title":"AASLD guidelines for treatment of chronic hepatitis B","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.236136-10","first-page":"370","volume-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","author":"European","year":"2017","journal-title":"J Hepatol"},{"key":"key-10.4103\/1319-3767.236136-11","first-page":"1163","volume-title":"The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: Predictive factors for dose reduction and treatment discontinuation","author":"van","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/1319-3767.236136-12","first-page":"1251","volume-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.236136-13","first-page":"3992","volume-title":"Inhibition of hepatitis B virus polymerase by entecavir","author":"Langley","year":"2007","journal-title":"J Virol"},{"key":"key-10.4103\/1319-3767.236136-14","first-page":"1486","volume-title":"Hepatitis B virus infection","author":"Dienstag","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.236136-15","first-page":"995","volume-title":"Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population","author":"Harris","year":"2003","journal-title":"Cancer Causes Control"},{"key":"key-10.4103\/1319-3767.236136-16","first-page":"167","volume-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","author":"European","year":"2012","journal-title":"J Hepatol"},{"key":"key-10.4103\/1319-3767.236136-17","first-page":"284","volume-title":", Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.236136-18","first-page":"504","volume-title":"Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting","author":"Idilman","year":"2015","journal-title":"J Viral Hepat"},{"key":"key-10.4103\/1319-3767.236136-19","first-page":"48","volume-title":"Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience","author":"Lovett","year":"2017","journal-title":"World J Hepatol"},{"key":"key-10.4103\/1319-3767.236136-20","doi-asserted-by":"crossref","unstructured":"Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011;141:1240-8, 48.e1-2.","DOI":"10.1053\/j.gastro.2011.06.036"},{"key":"key-10.4103\/1319-3767.236136-21","first-page":"694","volume-title":"Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load","author":"Sinn","year":"2015","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.236136-22","first-page":"1142","volume-title":"Increase in primary liver cancer in the UK, 1979-94","author":"Taylor-Robinson","year":"1997","journal-title":"Lancet"},{"key":"key-10.4103\/1319-3767.236136-23","doi-asserted-by":"crossref","unstructured":"Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009;44(Suppl. 19):102-7.","DOI":"10.1007\/s00535-008-2251-0"},{"key":"key-10.4103\/1319-3767.236136-24","first-page":"57","volume-title":"[Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B]","author":"Myung","year":"2010","journal-title":"Korean J Hepatol"},{"key":"key-10.4103\/1319-3767.236136-25","first-page":"1011","volume-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.236136-26","first-page":"1001","volume-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.236136-27","first-page":"2442","volume-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.236136-28","first-page":"e0130392","volume-title":"Comparison of the efficacy of entecavir and tenofovir in nucleos (t) ide analogue-experienced chronic hepatitis B patients","author":"Cho","year":"2015","journal-title":"PLoS One"},{"key":"key-10.4103\/1319-3767.236136-29","first-page":"305","volume-title":"Effectiveness of entecavir treatment and predictive factors for virologic response","author":"Preda","year":"2014","journal-title":"Rev Esp Enferm Dig"},{"key":"key-10.4103\/1319-3767.236136-30","first-page":"2463197","volume-title":"TDF monotherapy is effective regardless of prior nucleos(t)ide analogue treatment in chronic hepatitis B patients in China","author":"Huang","year":"2017","journal-title":"Biomed Res Int"},{"key":"key-10.4103\/1319-3767.236136-31","first-page":"186","volume-title":"Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B","author":"Perrillo","year":"2002","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.236136-32","first-page":"770","volume-title":"Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B.Asian Hepatitis Lamivudine Trial Group","author":"Chien","year":"1999","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.236136-33","first-page":"S306","volume-title":"755 5-year entecavir treatment in NUC-na\u00efve, field-practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics.J Hepatol","author":"Lampertico","year":"2013","journal-title":""},{"key":"key-10.4103\/1319-3767.236136-34","first-page":"653A","volume-title":"Four years of tenofovir monotherapy for NUC na\u00efve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis","author":"Lampertico","year":"2013","journal-title":"Hepatology"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:34:26Z","timestamp":1786714466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.SJG_49_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"alternative-id":["236136"],"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_49_18","relation":{},"ISSN":["1319-3767"],"issn-type":[{"value":"1319-3767","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}